Basilea Pharmaceutica AG (SWX:BSLN)

Market Cap	668.66M +37.4%
Revenue (ttm)	232.38M +11.4%
Net Income	40.24M -48.1%
EPS	3.14 -46.1%
Shares Out	12.29M
PE Ratio	17.31
Forward PE	12.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,490
Average Volume	39,843
Open	54.40
Previous Close	54.40
Day's Range	53.90 - 55.00
52-Week Range	37.50 - 59.70
Beta	0.45
RSI	45.02
Earnings Date	Feb 17, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 180
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.